"The fourth quarter capped off a spectacular year for Illumina with robust performance across all products and geographies. We made significant progress on key R&D programs which allowed us to introduce new products in early 2014 that will once again redefine the trajectory of sequencing. We plan to leverage this momentum in 2014 to more broadly enable the adoption of genomics." -- Jay Flatley, CEO
I continue to believe that we have entered the Genomics Age and Illumina is a solid genomics company.
From today (02014.01.29): "Mizuho raised its price target for Illumina shares to $175 citing the company's strong preannounced Q4 results and reiterates a Buy rating on the stock." I don't who Mizuho is, but I'd like to see ILMN at $175.
ILMN closed yesterday (02014.01.28) at $144.53. Today it hit a new 52-week high of $154.92. 52-week range: $48.00 - $154.92.
No comments:
Post a Comment